/Sunflower Pharmaceutical: Third Quarter Report of 2025

NEWS

Sunflower Pharmaceutical: Third Quarter Report of 2025

Shenzhen Stock Exchange

2025/10/28

Sunflower Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

Securities code: 002737 Securities abbreviation: Sunflower Pharmaceutical Announcement number: 2025-066

Sunflower Pharmaceutical Group Co., Ltd.

2025 Third Quarter Report

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions. Important content reminder:

The board of directors, the board of supervisors and directors, supervisors and senior managers guarantee that the quarterly report is true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.
The person in charge of the company, the person in charge of accounting work and the person in charge of the accounting department (accounting supervisor) declare that they guarantee the authenticity, accuracy and completeness of the financial information in the quarterly report.
Whether the third quarter financial accounting report has been audited

□Yes No

Sunflower Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

1. Main financial data

(1) Main accounting data and financial indicators

Whether the company needs to retroactively adjust or restate previous years’ accounting data

□Yes No

This reporting period from the beginning of the year to the end of the reporting period Increase or decrease in this reporting period compared with the same period of the previous year From the beginning of the reporting period to the end of the reporting period

Increase or decrease in operating income compared with the same period last year (yuan) 373,840,721.51 -14.90% 1,683,984,047.39 -43.24% Net profit attributable to shareholders of listed companies

-114,848,599.10 -214.27% -33,538,693.69 -105.72%Profit (yuan)

Deductions attributable to shareholders of listed companies

Net profit except recurring profits and losses -129,579,387.16 -17,557.21% -81,393,930.98 -117.68% (yuan)

cash flow from operating activities

— — 220,323,992.20 155.20% net amount (yuan)

Basic earnings per share (yuan/share) -0.20 -217.65% -0.06 -106.00% Diluted earnings per share (yuan/share) -0.20 -217.65% -0.06 -106.00% Weighted average return on equity -2.61% -4.88% -0.77% -13.09%

End of the reporting period End of the previous year Increase or decrease in total assets at the end of the reporting period compared with the end of the previous year (yuan) 5,123,453,375.74 5,825,875,967.73 -12.06% of all assets attributable to shareholders of the listed company

4,052,632,698.81 4,379,138,713.78 -7.46% owners’ equity (yuan)

(2) Non-recurring profit and loss items and amounts

Applicable □Not applicable

Unit: Yuan

Item Amount for this reporting period Amount from the beginning of the reporting period to the end of the reporting period Explanation

Gains and losses on disposal of non-current assets (including accrued

-1,165.69 652,556.91

The write-off portion of the asset impairment provision)

Government subsidies included in current profits and losses (with the company

Closely related to normal business operations and in compliance with the national

Policy provisions, enjoyment according to determined standards, 14,358,337.81 47,097,111.75

Government subsidies that have a lasting impact on the company's profits and losses

(except assistance)

Except for those related to the company’s normal business operations,

In addition to hedging business, non-financial enterprises hold

Fair value of financial assets and financial liabilities 8,997,672.82 25,950,121.51

Gains and losses from changes in value and disposal of financial assets and funds

Profit and loss arising from financial liabilities

Other non-operating income other than the above items

-3,027,621.33 -8,583,993.03

and expenses

Other gains and losses that meet the definition of non-recurring gains and losses

823,048.35

Project

Less: Income tax impact 4,849,474.50 15,463,443.93

Amount of impact on minority shareholders’ equity (after tax) 746,961.05 2,620,164.27

Total 14,730,788.06 47,855,237.29 --Details of other profit and loss items that meet the definition of non-recurring profits and losses:

□Applicable Not applicable

Sunflower Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

The company has no other specific circumstances of profit and loss items that meet the definition of non-recurring profits and losses.

Explanation on defining the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items

□Applicable Not applicable

The company does not define the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items.

(3) Changes in major accounting data and financial indicators and their reasons

Balance sheet items Unit: Yuan

Item Closing balance Beginning balance Changes Description of the situation

Monetary funds 685,498,468.48 1,040,228,908.13 -34.10% Mainly due to the decrease in sales during the reporting period.

Financing of receivables 43,596,703.91 369,744,164.58 -88.21% Mainly due to payment of operating funds during the reporting period. Mainly due to the increase in prepayments for purchases during the reporting period 83,559,262.85 56,259,736.01 48.52%

To.

Assets held for sale 2,040,535.38 -100.00% Mainly due to the completion of disposal of assets held for sale at the beginning of the year. Mainly due to prepaid taxes and other current assets to be deducted during the reporting period 34,341,121.78 61,612,332.36 -44.26%

Decrease in gold.

Mainly due to construction in progress required for installation by subsidiaries during the reporting period 46,778,958.22 30,835,547.91 51.70%

Due to the increase in machinery and equipment.

Mainly due to the subsidiary’s purchase of drug registration numbers and other non-current assets during the reporting period 52,667,235.56 23,677,579.88 122.44%

The transfer procedure has not been completed yet.

Mainly due to the subsidiary’s increase in short-term bank borrowings during the reporting period 18,000,000.00 22,093.47 81,372.04%

Caused by.

Mainly due to the salary accrued at the end of the previous year and the payment of employee benefits payable in the current period 67,586,943.36 165,286,636.67 -59.11%

To.

Mainly due to the decrease in contract liabilities from advance receipts during the reporting period compared with the beginning of the period 158,338,476.53 284,078,670.84 -44.26%

To.

Liabilities held for sale 304,840.00 -100.00% Mainly due to the completion of the disposal of liabilities held for sale at the beginning of the year. Non-currents due within one year are mainly lease liabilities due within one year during the reporting period 1,907,487.22 4,946,085.60 -61.43%

Liquid liabilities were due to the decrease in debt compared with the beginning of the period.

Mainly due to the decrease in lease liabilities during the reporting period compared with the beginning of the period: 1,838,608.96 4,026,380.06 -54.34%

Caused by less.

Mainly due to the reclassification of bank acceptance notes that have been endorsed and transferred by subsidiaries but other current liabilities 13,282,438.86 7,664,228.20 73.30% have not been derecognized during the reporting period.

Income statement and cash flow statement items

Item Amount for the current period Amount for the same period Changes Description of the situation

Operating income 1,683,984,047.39 2,966,906,461.88 -43.24% Mainly due to the decrease in sales during the reporting period.

Mainly due to the decrease in sales and enhancement fee sales expenses during the reporting period 336,479,049.08 540,060,782.14 -37.70%

Caused by control.

Financial expenses -3,924,399.11 -21,732,226.50 81.94% Mainly due to the decrease in bank interest income in the current period. Mainly due to the change in fair value of fund investments during the reporting period: 5,084,930.96 -3,573,110.59 242.31%

Caused by movement.

Mainly due to the increase in investment income from financial products during the reporting period 19,675,919.34 12,785,310.25 53.89%

To.

Mainly due to the decrease in credit impairment losses during the reporting period compared with the same period -3,170,015.65 -21,286,655.05 -85.11%

Caused by.

Mainly due to the increase in asset impairment losses due to the provision for inventory depreciation during the reporting period -6,839,558.04 -3,649,650.60 87.40%

Caused by.

Mainly due to the increase in income from asset disposal during the reporting period. Profit and loss from asset disposal 652,556.91 -185,101.90 452.54%

To.

Non-operating income 124,113.98 5,742,043.30 -97.84% Mainly due to the receipt of donations during the same period.

Sunflower Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

Non-operating expenses 8,708,107.01 2,570,616.22 238.76% Mainly due to the payment of taxes during the reporting period.

Income tax expenses 39,679,584.12 138,852,550.27 -71.42% Mainly due to the decrease in total profits during the reporting period.

Net profit -45,914,346.86 605,513,521.75 -107.58% Mainly due to the decrease in sales during the reporting period. Cash generated from operating activities mainly refers to cash paid for goods purchased during the reporting period.

220,323,992.20 -399,173,131.02 155.20%

Net cash flow was due to the decrease in cash flow.

The cash generated from investment activities is mainly due to the purchase of financial products during the reporting period compared with the same period.

-276,914,999.75 254,800,846.26 -208.68%

Due to the increase in net cash flow.

The cash generated from financing activities is mainly due to the decrease in dividends distributed during the reporting period compared with the same period.

-296,007,935.81 -942,799,929.09 68.60%

Net cash flow.

Applicable □Not applicable

2. Shareholder information

(1) The total number of common shareholders, the number of preferred shareholders whose voting rights have been restored, and the shareholding status of the top ten shareholders

Unit: Share

Preference shareholders whose voting rights are restored at the end of the reporting period

Total number of common shareholders at the end of the reporting period 52,430 0 Total number (if any)

Shareholding status of the top 10 shareholders (excluding shares lent through refinancing)

Holding limited Pledge, mark or freeze Name of shareholder Nature of shareholder Shareholding ratio Number of shares held Sale conditions

Share Status Quantity

Number of shares

Sunflower Group Co., Ltd. Domestic non-state-owned legal person 45.41% 265,200,000 0 Not applicable 0 Guan Yanbin Domestic natural person 6.03% 35,220,422 0 Not applicable 0 Heilongjiang Jinkui Investment Co., Ltd. Domestic non-state-owned legal person 4.11% 24,000,000 0 Not applicable 0 Zhang Quan Domestic natural persons 0.60% 3,479,874 0 Not applicable 0 Bank of China Co., Ltd.-Yifang

CSI Dividend Trading Open-End Index Others 0.58% 3,400,829 0 Not applicable 0 Securities Investment Fund

Li Jie Domestic natural person 0.56% 3,281,648 0 Not applicable 0 Hong Kong Securities Clearing Company Limited Overseas legal person 0.49% 2,841,187 0 Not applicable 0 Shanghai Pudong Development Bank Co., Ltd.

Company - China Merchants Securities Dividend Trading Type Open Others 0.49% 2,838,228 0 Not applicable 0-type index securities investment fund

China Merchants Bank Co., Ltd.-Southern

CSI 1000 Trading Open Index Others 0.46% 2,675,700 0 Not applicable 0 Securities investment funds

Zhang Yuling Domestic natural person 0.34% 2,008,400 0 Not applicable 0 Shareholdings of the top 10 shareholders without selling restrictions (excluding shares lent through refinancing and shares locked by executives)

Type and quantity of shares

Name of shareholder Number of shares without selling restrictions held

Type of shares Quantity Sunflower Group Co., Ltd. 265,200,000 RMB ordinary shares 265,200,000 Guan Yanbin 35,220,422 RMB ordinary shares 35,220,422 Heilongjiang Jinkui Investment Co., Ltd. 24,000,000 RMB ordinary shares 24,000,000 Rights 3,479,874 RMB ordinary shares 3,479,874 Bank of China Co., Ltd.-E Fund CSI Dividend Trading Type

3,400,829 RMB ordinary shares 3,400,829 Open-ended index securities investment funds

Li Jie 3,281,648 RMB ordinary shares 3,281,648 Hong Kong Securities Clearing Company Limited 2,841,187 RMB ordinary shares 2,841,187 Shanghai Pudong Development Bank Co., Ltd. - China Merchants Securities Dividend Exchange

2,838,228 RMB ordinary shares 2,838,228 Easy open-end index securities investment fund

China Merchants Bank Co., Ltd.-South China Securities 1000 Trading Type

2,675,700 RMB ordinary shares 2,675,700 Open index securities investment funds

Zhang Yuling 2,008,400 RMB ordinary shares 2,008,400 Explanation of related relationships or concerted actions among the above shareholders 1. Mr. Guan Yanbin is a member of Sunflower Group Co., Ltd., Heilongjiang Jinkui Investment Co., Ltd.

Sunflower Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

The largest shareholder of the company; 2. Li Jie is a participating shareholder of Sunflower Group Co., Ltd.; 3. Zhang Quan is

Director and shareholder of Sunflower Group Co., Ltd.

Description of the top 10 shareholders’ participation in margin trading and securities lending business (if any) The controlling shareholder, actual controller and persons acting in concert have not conducted margin trading and securities lending business.

The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares

□Applicable Not applicable

The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.

□Applicable Not applicable

(2) Total number of preferred shareholders of the company and shareholding status of the top 10 preferred shareholders

□Applicable Not applicable

3. Other important matters

□Applicable Not applicable

4. Quarterly Financial Statements

(1) Financial statements

Consolidated balance sheet

Prepared by: Sunflower Pharmaceutical Group Co., Ltd.

September 30, 2025

Unit: Yuan

Item Ending balance Beginning balance

Current assets:

Monetary funds 685,498,468.48 1,040,228,908.13 Settlement reserves

Loan funds

Trading financial assets 1,500,000,000.00 1,258,256,600.00 Derivative financial assets

Notes receivable 7,631,609.22 7,449,631.47 Accounts receivable 218,154,650.45 207,740,418.62 Receivables financing 43,596,703.91 369,744,164.58 Advance payments 83,559,262.85 56,259,736.01 Premium receivable

Reinsurance accounts receivable

Receivable reinsurance contract reserves

Other receivables 13,244,485.15 14,949,966.36 Including: interest receivable

Dividends receivable

Buy financial assets under resale agreements

Inventory 675,296,680.05 867,310,798.53

Among them: data resources

contract assets

Assets held for sale 2,040,535.38 Non-current assets due within one year

Other current assets 34,341,121.78 61,612,332.36 Total current assets 3,261,322,981.89 3,885,593,091.44 Non-current assets:

Grant loans and advances

Sunflower Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

debt investment

Other debt investments

long-term receivables

Long-term equity investment 39,211,095.84 43,193,367.08 Other equity instrument investment 2,800,634.40 2,832,084.00 Other non-current financial assets 51,193,806.18 51,091,886.22 Investment real estate 39,400,945.44 41,211,563.37 Fixed assets 1,180,476,715.34 1,270,540,325.86 Construction in progress 46,778,958.22 30,835,547.91 Productive biological assets

oil and gas assets

Right-of-use assets 4,782,005.26 9,624,358.14 Intangible assets 313,715,247.37 332,644,765.73

Among them: data resources

development expenditure

Among them: data resources

Goodwill 86,976,128.04 86,976,128.04 Long-term deferred expenses 7,667,685.57 10,033,785.82 Deferred income tax assets 36,459,936.63 37,621,484.24 Other non-current assets 52,667,235.56 23,677,579.88 Total non-current assets 1,862,130,393.85 1,940,282,876.29 Total assets 5,123,453,375.74 5,825,875,967.73 Current liabilities:

Short-term borrowings 18,000,000.00 22,093.47 Borrowings from the central bank

borrowing funds

Trading financial liabilities

Derivative financial liabilities

Notes payable 8,451,319.65

Accounts payable 256,841,198.58 319,049,382.33 Advance receipts 1,177,370.00 1,601,223.20 Contract liabilities 158,338,476.53 284,078,670.84 Financial assets sold under repurchase agreements

Taking deposits and placing deposits with other banks

Agent for buying and selling securities

Agent underwriting securities funds

Employee benefits payable 67,586,943.36 165,286,636.67 Taxes payable 18,920,016.18 46,294,854.72 Other payables 176,009,130.63 198,278,235.84 Including: interest payable

Dividends payable

Handling fees and commissions payable

Reinsurance accounts payable

Liabilities held for sale 304,840.00 Non-current liabilities due within one year 1,907,487.22 4,946,085.60 Other current liabilities 13,282,438.86 7,664,228.20 Total current liabilities 720,514,381.01 1,027,526,250.87 Non-current liabilities:

insurance contract reserves

long term borrowing

bonds payable

Among them: preferred shares

perpetual bond

Lease liabilities 1,838,608.96 4,026,380.06 Long-term payables

Long-term employee benefits payable

Sunflower Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

Estimated liabilities

Deferred income 165,566,371.55 199,371,625.41 Deferred income tax liabilities 3,634,728.94 4,952,502.12 Other non-current liabilities

Total non-current liabilities 171,039,709.45 208,350,507.59 Total liabilities 891,554,090.46 1,235,876,758.46 Owners’ equity:

Share capital 584,000,000.00 584,000,000.00 Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve 918,428,406.13 918,428,406.13 less: treasury shares

Other comprehensive income -182,438.10 -163,725.59Special reserve 8,379,856.55 9,328,465.32 Surplus reserve 299,866,501.83 299,866,501.83General risk reserve

Undistributed profits 2,242,140,372.40 2,567,679,066.09 Total owners’ equity attributable to the parent company 4,052,632,698.81 4,379,138,713.78 Minority shareholders’ equity 179,266,586.47 210,860,495.49 Total owners’ equity 4,231,899,285.28 4,589,999,209.27 Total liabilities and owners’ equity 5,123,453,375.74 5,825,875,967.73 Legal representative: Guan Yuxiu Person in charge of accounting work: Wu Chunhong Person in charge of accounting department: Chen Li

Consolidated income statement from the beginning of the year to the end of the reporting period

Unit: Yuan

Item Amount for the current period Amount for the previous period

Total operating income 1,683,984,047.39 2,966,906,461.88 Including: operating income 1,683,984,047.39 2,966,906,461.88 Interest income

Premiums earned

Fee and commission income

Total operating costs 1,747,427,250.48 2,354,275,676.31

Including: operating costs 1,049,911,737.15 1,417,182,527.64

interest expense

Handling fees and commission expenses

surrender deposit

Net compensation expenses

Net withdrawal of insurance liability reserves

policy dividend payout

Reinsurance cost

Taxes and surcharges 28,130,414.92 38,708,788.97 Sales expenses 336,479,049.08 540,060,782.14

Management expenses 270,722,708.22 300,622,453.51

Research and development expenses 66,107,740.22 79,433,350.55

Financial expenses -3,924,399.11 -21,732,226.50

Including: interest expenses 1,219,173.87 1,619,717.18

Interest income 5,569,374.47 24,133,291.74

Add: other income 50,388,599.86 144,473,067.26

Investment income (losses are filled in with "-" 19,675,919.34 12,785,310.25

Sunflower Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

column)

Of which: for associates and joint ventures

-1,189,271.21 -1,308,449.36 Enterprise investment income

Measured at amortized cost

Income from derecognition of financial assets

Exchange gains (losses are filled in with "-"

column)

Net exposure hedging gain (loss calculated as

Fill in the column with "-" sign)

Gains from changes in fair value (losses calculated as

5,084,930.96 -3,573,110.59 (Fill in “-”)

Credit impairment losses (losses are marked with "-"

-3,170,015.65 -21,286,655.05 fill in the column)

Asset impairment losses (losses are marked with "-"

-6,839,558.04 -3,649,650.60 fill in the column)

Asset disposal income (losses are marked with "-"

652,556.91 -185,101.90 fill in the column)

3. Operating profit (loss is filled in with "-"

2,349,230.29 741,194,644.94 columns)

Add: Non-operating income 124,113.98 5,742,043.30 Less: Non-operating expenses 8,708,107.01 2,570,616.22

4. Total profit (total loss is marked with "-"

-6,234,762.74 744,366,072.02 fill in the column)

Less: Income tax expense 39,679,584.12 138,852,550.27

5. Net profit (net loss is filled in with "-"

-45,914,346.86 605,513,521.75 columns)

(1) Classification by business continuity

Net profit from continuing operations (net loss divided by

-45,914,346.86 605,513,521.75 (Fill in “-”)

Net profit from discontinued operations (net loss equal to

Fill in the column with "-" sign)

(2) Classification according to ownership ownership

Net profit attributable to shareholders of the parent company

-33,538,693.69 586,835,406.50 (Net loss is listed with "-")

Profit and loss of minority shareholders (net loss is represented by “-”

-12,375,653.17 18,678,115.25 (please fill in the list)

Net after-tax amount of other comprehensive income -26,732.16 120,556.80 Other comprehensive income attributable to owners of the parent company

-18,712.51 84,389.76 net amount after tax

(1) Others that cannot be reclassified into profit or loss

-18,712.51 84,389.76 Comprehensive income

Remeasure changes in defined benefit plans

Others that cannot be transferred to profit or loss under the equity method

Comprehensive income

Fair value of other equity instrument investments

-18,712.51 84,389.76 change

Fair value of the company’s own credit risk

change

5.Others

(2) Other comprehensive items that will be reclassified into profit or loss

combined income

Other comprehensive items that can be transferred to profits and losses under the equity method

combined income

Changes in fair value of other debt investments
Financial assets are reclassified into other comprehensive

Sunflower Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

Amount of combined income

Credit impairment provisions for other debt investments
Cash flow hedging reserve
Translation differences of foreign currency financial statements

7.Others

Other comprehensive income attributable to minority shareholders

-8,019.65 36,167.04 Net after tax

Total comprehensive income -45,941,079.02 605,634,078.55

(1) Comprehensive assets attributable to owners of the parent company

-33,557,406.20 586,919,796.26 Total income

(2) Comprehensive income attributable to minority shareholders

-12,383,672.82 18,714,282.29 total

8. Earnings per share:

(1) Basic earnings per share -0.06 1.00

(2) Diluted earnings per share -0.06 1.00 If a business merger under the same control occurs in this period, the net profit realized by the merged party before the merger is: yuan, and the net profit realized by the merged party in the previous period is: yuan.

Legal representative: Guan Yuxiu Person in charge of accounting work: Wu Chunhong Person in charge of accounting department: Chen Li

Consolidated cash flow statement from the beginning of the year to the end of the reporting period

Unit: Yuan

Item Amount for the current period Amount for the previous period

1. Cash flow generated from operating activities:

Cash received from selling goods and providing services 1,558,594,617.29 2,506,428,102.71 Net increase in customer deposits and deposits from banks

Net increase in borrowing from the central bank

Net increase in borrowing funds from other financial institutions

Cash received from premiums from the original insurance contract

Net cash received from reinsurance business

Net increase in policyholders’ savings and investment funds

Cash collected from interest, fees and commissions

Net increase in borrowing funds

Net increase in repurchase business funds

Net cash received from buying and selling securities on behalf of agents

tax refund received

Other cash received related to operating activities 128,347,590.48 103,796,244.88 Subtotal cash inflow from operating activities 1,686,942,207.77 2,610,224,347.59 Cash paid for purchasing goods and receiving services 420,794,433.08 1,362,767,421.20

Net increase in loans and advances to customers

Net increase in deposits with central banks and inter-banks

Cash used to pay compensation from the original insurance contract

Net increase in lending funds

Cash payments for interest, fees and commissions

Cash payment for policy dividends

Cash paid to and for employees 440,849,607.04 500,063,667.36 Various taxes and fees paid 171,412,976.09 422,334,340.22 Cash paid for other operating activities 433,561,199.36 724,232,049.83 Subtotal cash outflow from operating activities 1,466,618,215.57 3,009,397,478.61 Net cash flow generated from operating activities 220,323,992.20 -399,173,131.02

2. Cash flow generated from investing activities:

Cash received from recovery of investment 8,119,116,312.91 3,400,000,000.00 Cash received from investment income 31,198,234.44 31,159,586.70 Disposal of fixed assets, intangible assets and other long-term assets 191,876.00 1,110,995.00

Sunflower Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

Net cash received from period assets

Received from disposal of subsidiaries and other business units

net cash

Other cash received related to investing activities

Subtotal of cash inflows from investing activities 8,150,506,423.35 3,432,270,581.70 Purchase and construction of fixed assets, intangible assets and other long-term assets

67,421,423.10 77,469,735.44 Cash paid for assets

Cash paid for investment 8,360,000,000.00 3,100,000,000.00 Net increase in pledged loans

Obtain payment from subsidiaries and other business units

net cash

Other cash payments related to investing activities

Subtotal of cash outflows from investing activities 8,427,421,423.10 3,177,469,735.44 Net cash flow generated from investing activities -276,914,999.75 254,800,846.26

3. Cash flow generated from financing activities:

Absorbing cash received from investments

Among them: subsidiaries absorb investment from minority shareholders

cash received

Cash received from borrowing 18,000,000.00

Other cash received related to financing activities

Subtotal of cash inflows from financing activities 18,000,000.00

Cash paid to repay debts 10,000,000.00 Paid to distribute dividends, profits or pay interest

310,506,399.09 925,333,602.58 cash

Including: Payments made by subsidiaries to minority shareholders

18,947,768.05 40,631,072.20 Dividends and profits

Cash payments related to other financing activities 3,501,536.72 7,466,326.51 Subtotal cash outflows from financing activities 314,007,935.81 942,799,929.09 Net cash flow generated from financing activities -296,007,935.81 -942,799,929.09

4. The impact of exchange rate changes on cash and cash equivalents

65,213.33 -536,068.85 impact

Net increase in cash and cash equivalents -352,533,730.03 -1,087,708,282.70

Add: Balance of cash and cash equivalents at the beginning of the period 1,037,960,698.51 2,285,705,205.89

Balance of cash and cash equivalents at the end of the period 685,426,968.48 1,197,996,923.19

(2) Adjustment of relevant items in the financial statements at the beginning of the year when the new accounting standards are first implemented starting from 2025